Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (RadVax)

  • STATUS
    Recruiting
  • End date
    Feb 23, 2025
  • participants needed
    52
  • sponsor
    Abramson Cancer Center of the University of Pennsylvania
Updated on 23 April 2022

Summary

The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.

Details
Condition Metastatic Melanoma
Treatment Ipilimumab, Nivolumab, Hypofractionated radiation therapy (HFRT)
Clinical Study IdentifierNCT03646617
SponsorAbramson Cancer Center of the University of Pennsylvania
Last Modified on23 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed metastatic melanoma
Have at least two measurable lesions (including the index lesion) according to RECIST guidelines v1.1
Have an index lesion measuring between 1cm - 7cm that is amenable to HFRT radiation therapy at the discretion of the treating radiation oncologist
Able to tolerate HFRT (e.g. lie flat and hold position for treatment)
Able to provide signed, written informed consent and age > 18 years at time of signing
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Recovery from the adverse effects of prior cancer treatments, defined as effects having resolved to NCI CTCAE v5 Grade 1 or better with the exception of alopecia. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by nivolumab and ipilimumab may be included (eg, hearing loss, neuropathy) upon approval of the PI
Female subjects of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for two weeks before the time of the first dose of study medication, while on study, through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
Non-sterilized male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Acceptable forms of birth control include condoms, diaphragms, cervical cap, an intra-uterine device (IUD), surgical sterility (tubal ligation or a partner that has undergone a vasectomy), or oral contraceptives, OR the subject must agree to completely abstain from heterosexual intercourse. Abstinence at certain times of the cycle only, such as during the days of ovulation, after ovulation and withdrawal are not acceptable methods of birth control
Demonstrate adequate organ function; all screening labs should be performed within 21 days of date of consent
White blood cell >= 2,500 cells/ul
Absolute neutrophil count (ANC) ≥1,500 /mcL
Platelets >=100,000 / mcL
Hemoglobin >=9 g/dL
Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) <=1.5 X upper limit of normal (ULN) OR >=60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (Creatinine clearance should be calculated per institutional standard.)
Serum total bilirubin <= 1.5 X ULN OR
Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 ULN
AST (SGOT) and ALT (SGPT) <= 2.5 X ULN OR <= 5 X ULN for subjects with liver metastases

Exclusion Criteria

Central nervous system (CNS) metastases requiring urgent local therapy; patients with carcinomatous meningitis are excluded. If there is clinical suspicion of brain metastases, a brain MRI should be obtained
Concurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional study
Prior therapy with an anti-PD-1 (including nivolumab), anti-PD-L1, anti-PDL2, or anti-CTLA4 (including ipilimumab) agents, interferon, HD IL-2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. Prior adjuvant PD-1 blockade (but not prior adjuvant CTLA-4 blockade) is permitted
Concurrent treatment with any anticancer agent, including chemotherapy, immunotherapy, or biologic therapy
Treatment with any other investigational agent within 4 weeks prior to first dose of nivolumab/ipilimumab
Prior chemotherapy, targeted small molecule therapy or other anti-cancer therapy within 2 weeks prior to first dose of nivolumab/ipilimumab or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify
for the study
Known hypersensitivity to nivolumab, ipilimumab, monoclonal antibodies or
immunoglobulin G
Major surgical procedure (as defined by the investigator) within 28 days prior to the
first dose of nivolumab/ipilimumab or still recovering from prior surgery
History of primary immunodeficiency or tuberculosis
Current or prior use of immunosuppressive medication within 14 days before the first
dose of nivolumab/ipilimumab with the exceptions of intranasal, topical and inhaled
corticosteroids, systemic corticosteroids at physiologic doses not to exceed 10 mg/day
of prednisone or equivalent, or steroids used transiently to control contrast agent
allergies for radiographic studies
Active or prior documented autoimmune disease (including inflammatory bowel disease
diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel
disease, Wegner syndrome, Hashimoto syndrome) within the past year. Subjects with
vitiligo, alopecia, Grave's disease, or psoriasis not requiring systemic treatment
(within the past year) are not excluded. Patients with hypothyroidism stable on
thyroid replacement therapy for the previous 3 months are not excluded
Known true positive results for HIV or known active Hepatitis B (e.g. HBsAg reactive)
or Hepatitis C (e.g. HCV RNA [qualitative] is detected) as determined by medical
record review
Receipt of a live, attenuated vaccine within 28 days prior to the first dose of
nivolumab/ipilimumab. (NOTE: subjects, if enrolled, should not receive live vaccine
during the study or for 180 days after the last dose of both drugs)
Clinical contraindication to hypofractionated radiation as determined by the
investigator (e.g., active systemic sclerosis, active inflammatory bowel disease if
bowel is within radiation field.)
Prior radiotherapy that precludes the proposed treatment with HFRT or any radiotherapy
within 28 days of first dose of nivolumab/ipilimumab
Females who are pregnant, lactating, or intend to become pregnant during the
participation of the study
Uncontrolled inter-current illness, including, but not limited to, ongoing or active
infection, current pneumonitis, symptomatic congestive heart failure, uncontrolled
hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease
or psychiatric illness/social situations that would limit compliance with study
requirement or compromise the ability of the subject to give written informed consent
Other active invasive malignancy. History of non-invasive malignancies such as
cervical carcinoma in situ, non-melanomatous carcinoma of the skin, or ductal
carcinoma in situ of the breast is allowed, as is history of other invasive malignancy
that is in remission after treatment with curative intent
Any condition that, in the opinion of the investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or study
results
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note